Clinical Trials Logo

Consent Form clinical trials

View clinical trials related to Consent Form.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT03992664 Active, not recruiting - Breast Cancer Clinical Trials

Education Intervention in Patients With Rash Due to Epidermal Growth Factor Receptor (EGFR) Treatment.

EGFR
Start date: January 1, 2019
Phase: N/A
Study type: Interventional

The main adverse reaction of EGFR seen in patients is rash. EGFR treated patients have a 24-95% incidence of rash depending on the type of treatment they receive. Skin toxicity may occur in more than 80% of patients treated with cetuximab. If a severe rash (Grade 3 or 4) occurs, a dose reduction or discontinuation of treatment may be required. Also, infections are the main secondary side effect caused by the rash. The aim of the study is through a randomized clinical trial feasibility study to investigate the effectiveness of an educational intervention in patients receiving EGFRI therapy. It will be randomly selected which patients will belong to the intervention group and who in the control group. The type of program involves educational intervention.